Colon cancer doesn’t directly cause thyroid problems in most cases, but there are several real connections between the two. Some inherited conditions that cause colon cancer also raise thyroid cancer risk. Colon cancer treatments, particularly immunotherapy and targeted drugs, can disrupt thyroid function. And in rare instances, colon cancer can physically spread to the thyroid gland. Understanding which scenario applies to you makes a big difference.
Genetic Syndromes That Link Both Cancers
The strongest direct connection between colon and thyroid cancer is a hereditary condition called familial adenomatous polyposis (FAP). FAP is caused by mutations in the APC gene and leads to hundreds of polyps in the colon, dramatically raising colon cancer risk. It also increases the lifetime risk of papillary thyroid cancer to about 1 to 2 percent, which is notably higher than the general population’s baseline risk.
The thyroid cancers that develop in FAP patients tend to be a distinctive type called cribriform-morular variant papillary thyroid carcinoma. This rare variant has unusual features under the microscope: cells arranged in papillary and lattice-like patterns with characteristic clusters called morules and no colloid (the protein-rich material normally stored in thyroid tissue). It occurs almost exclusively in the context of FAP, so finding this type of thyroid cancer sometimes leads doctors to investigate for undiagnosed colon polyps.
American College of Gastroenterology guidelines recommend annual thyroid ultrasound for people with FAP. Some centers, including the Cleveland Clinic, have suggested that if a baseline ultrasound is normal, screening could be extended to every two years until nodules appear. European and Japanese guidelines take a less aggressive stance and don’t favor routine thyroid surveillance in FAP patients. If you carry an FAP diagnosis, ask your care team which screening schedule makes sense for your situation.
How Colon Cancer Treatment Affects the Thyroid
This is probably the most common way colon cancer leads to thyroid problems, and it catches many patients off guard. Several drugs used to treat advanced colorectal cancer can directly impair thyroid function.
Immunotherapy drugs, particularly checkpoint inhibitors that target PD-1 or CTLA-4, trigger thyroid dysfunction at significant rates. PD-1 inhibitors cause hypothyroidism (an underactive thyroid) in 9 to 40 percent of patients and hyperthyroidism (an overactive thyroid) in 1 to 13 percent. When PD-1 and CTLA-4 inhibitors are combined, hyperthyroidism rates climb to 22 to 30 percent. These drugs work by releasing the brakes on the immune system, which sometimes causes the immune system to attack the thyroid gland as collateral damage.
Targeted therapies called tyrosine kinase inhibitors can also damage the thyroid through multiple pathways: triggering inflammation in the gland, shrinking its blood supply, interfering with iodine uptake, and prompting the body to produce antibodies against thyroid tissue. Some patients experience a brief phase of overactive thyroid followed by a longer period of underactive thyroid. Bevacizumab, a drug approved for colorectal cancer that blocks blood vessel growth in tumors, has also been linked to hypothyroidism, though at lower rates than other targeted therapies.
If you’re receiving any of these treatments for colon cancer and notice fatigue, unexplained weight changes, feeling unusually cold, or a racing heart, thyroid dysfunction is a real possibility. Routine thyroid blood tests during treatment can catch these changes early, and most cases are manageable with thyroid hormone replacement.
When Colon Cancer Spreads to the Thyroid
Colon cancer metastasizing directly to the thyroid gland is genuinely rare. Metastatic tumors account for only 1.4 to 3 percent of all malignant thyroid tumors found clinically, and colorectal cancer is one of the less common origins. Lung, kidney, breast, and esophageal cancers metastasize to the thyroid more frequently. Autopsy studies find a higher rate of thyroid metastases (around 9.5 percent), suggesting many cases never produce noticeable symptoms during a patient’s lifetime.
Diagnosing these metastases is tricky. In a review of 42 patients who had thyroid biopsies, only about 36 percent of confirmed cases were correctly identified as colorectal cancer spread to the thyroid. The rest were initially misdiagnosed as primary thyroid cancer or cancer of unknown origin. Pathologists can distinguish between the two using specific protein markers: colorectal metastases typically test positive for CDX-2 and CK20 while testing negative for thyroid-specific markers like TTF-1 and thyroglobulin. Getting this distinction right matters because treatment for a colorectal metastasis is very different from treatment for primary thyroid cancer.
Shared Risk Factors Behind Both Conditions
Even without a direct causal relationship, colon problems and thyroid problems often show up in the same people because they share underlying risk factors. Metabolic syndrome, the cluster of conditions that includes obesity, high blood sugar, high blood pressure, and abnormal cholesterol, independently raises the risk of both colorectal polyps and thyroid nodules.
The connecting thread appears to be insulin resistance. When cells stop responding normally to insulin, the body compensates by producing more of it. Elevated insulin increases levels of a growth factor called IGF-1 while decreasing its binding proteins, creating an environment that promotes abnormal cell growth. This mechanism has been implicated in both colorectal adenoma development and thyroid nodule formation.
A large study found that thyroid nodules and metabolic syndrome are each independent risk factors for colorectal polyps. More notably, when both conditions were present together, they had a compounding effect on colorectal adenoma risk, with 38.4 percent of adenomas in that group attributed to the overlap of the two conditions. This doesn’t mean thyroid nodules cause colon polyps or vice versa, but it does mean that if you have one, screening for the other may be worthwhile, especially if you also carry metabolic risk factors like abdominal obesity or insulin resistance.